Literature DB >> 698954

Prolactin and the development and progression of early neoplastic mammary gland lesions.

C W Welsch.   

Abstract

Chronic suppression of prolactin by 2-bromo-alpha-ergocryptine (CB-154) in young nulliparous or mature multiparous C3H mice sharply suppressed the development of preneoplastic mammary gland lesions (hyperplastic alveolar nodules) and markedly inhibited the progression of these preneoplasias to carcinomas. This effect was also observed in C3H mice treated with either 17beta-estradiol or the oral contraceptive Enovid. Chronic CB-154 induced prolactin suppression was more effective than ovariectomy in the suppression of hyperplastic alveolar nodule development and comparable to ovariectomy in the suppression of mammary carcinoma development. Evidence is also provided indicating that human placental lactogen, a peptide chemically and physiologically similar to prolactin, promotes growth both in vitro (organ culture) and in vivo (athymic "nude" mouse) of the epithelium contained in benign human breast tumors. Whether or not human pituitary prolactin is capable of mimicking the mammotrophic action of human placental lactogen and whether a dysplastic, prolactin-sensitive lesion comparable to hyperplastic alveolar nodules exists in the human breast remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698954

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  The Use and Misuse of Historical Controls in Regulatory Toxicology: Lessons from the CLARITY-BPA Study.

Authors:  Laura N Vandenberg; Gail S Prins; Heather B Patisaul; R Thomas Zoeller
Journal:  Endocrinology       Date:  2020-05-01       Impact factor: 4.736

2.  Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor.

Authors:  J F Sissom; M L Eigenbrodt; J C Porter
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

Review 3.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 4.  Role of hormones in mammary cancer initiation and progression.

Authors:  I H Russo; J Russo
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

6.  Structure and function of a new class of human prolactin antagonists.

Authors:  Laura DePalatis; Colleen M Almgren; Jypji Patmastan; Mark Troyer; Todd Woodrich; Charles L Brooks
Journal:  Protein Expr Purif       Date:  2009-02-21       Impact factor: 1.650

Review 7.  Xenograft models of premalignant breast disease.

Authors:  F R Miller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 8.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

Review 9.  Mammary gland neoplasia in long-term rodent studies.

Authors:  I H Russo; J Russo
Journal:  Environ Health Perspect       Date:  1996-09       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.